Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: An overview

Obstetrical and Gynecological Survey

Volumn 60, Issue 9, 2005, Pages 604-612

  Jensen, Jeffrey T ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Berlex Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; COPPER INTRAUTERINE DEVICE; ESTRADIOL; FLURBIPROFEN; GESTAGEN; LEVONORGESTREL; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PROSTAGLANDIN INHIBITOR; TRANEXAMIC ACID;

AMENORRHEA; ANEMIA; BREAKTHROUGH BLEEDING; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTINUING EDUCATION; CONTRACEPTIVE DEVICE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ECTOPIC PREGNANCY; ENDOMETRIOSIS; ENDOMETRIUM; ENDOMETRIUM ABLATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; FEMALE FERTILITY; HEALTH ECONOMICS; HORMONAL CONTRACEPTION; HUMAN; HYSTERECTOMY; INFECTION RISK; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSAL SYNDROME; MENORRHAGIA; MENSTRUATION; META ANALYSIS; METRORRHAGIA; PATIENT COUNSELING; PELVIC INFLAMMATORY DISEASE; PREGNANCY RATE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UTERUS MYOMA;

CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; UTERINE HEMORRHAGE;

EID: 23944513757     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ogx.0000175805.90122.af     Document Type: Review

References (79)

1. Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997;90:257-263.
2. Jensen JT. Noncontraceptive applications of the levonorgestrel intrauterine system. Curr Womens Health Rep 2002;2: 417-422.
3. Suvanto-Luukkonen E, Kauppila A. The levonorgestrel intrauterine system in menopausal hormone replacement therapy: five-year experience. Fertil Steril 1999;72:161-163.
4. Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995;172:114-119.
5. Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002; 109:136-144.
6. Nilsson CG, Lahteenmaki PL, Luukkainen T, et al. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril 1986;45:805-807.
7. Lahteenmaki P, Nilsson CG. Plasma concentrations of ethynylestradiol and D-norgestrel during two immediate postabortal oral contraceptive cycles. Contraception 1978;17:9-17.
8. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann N Y Acad Sci 1991;626:43-49.
9. Luukkainen T, Lahteenmaki P, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90.
10. Xiao B, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception 1995;51:359-365.
11. Nilsson CG, Haukkamaa M, Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf) 1982;17:529-536.
12. Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a d-norgestrel-releasing intrauterine device. Fertil Steril 1978;29:397-401.
13. Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986;5:235-241.
14. Johannisson E. Mechanism of action of intrauterine devices: biochemical changes. Contraception 1987;36:11-22.
15. Jonsson B, Landgren BM, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991; 43:447-458.
16. Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 1995;11:85-95.
17. Aref I, Reda M, Kandil O, et al. Postcoital recovery of sperm in Douglas pouch aspirates of infertile patients. Int J Gynaecol Obstet 1984;22:29-34.
18. Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception 1987;36:37-53.
19. Mandelin E, Koistinen H, Koistinen R, et al. Levonorgestrel-releasing intrauterine device-wearing women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Hum Reprod 1997;12: 2671-2675.
20. Alvarez F, Brache V, Fernandez E, et al. New insights on the mode of action of intrauterine contraceptive devices in women. Fertil Steril 1988;49:768-773.
21. Critchley HO, Wang H, Kelly RW, et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998;13:1210-1217.
22. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984;41:52-55.
23. Rutanen EM, Salmi A, Nyman T. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-1 are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol Hum Reprod 1997;3:749-754.
24. Rutanen EM. Insulin-like growth factors and insulin-like growth factor binding proteins in the endometrium. Effect of intrauterine levonorgestrel delivery. Hum Reprod 2000; 15(suppl3):173-181.
25. Maruo T, Laoag-Fernandez JB, Pakarinen P, et al. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod 2001; 16:2103-2108.
26. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. Contraception 1987;36:169-179.
27. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261-264.
28. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994; 49:56-72.
29. Baveja R, Bichille LK, Coyaji KJ, et al. Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device [LNG], CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD. Contraception 1989;39:37-52.
30. Sivin I, el Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20 meg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990;42:361-378.
31. Sivin I, Stern J, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS. Contraception 1991;44:473-480.
32. Davie JE, Walling MR, Mansour DJ, et al. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996;18:150-159.
33. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use. Acta Obstet Gynecol Scand 1999;78:716-721.
34. Pakarinen P, Toivonen J, Luukkainen T. Randomized comparison of levonorgestrel- and copper-releasing intrauterine systems immediately after abortion, with 5 years' follow-up. Contraception 2003;68:31-34.
35. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users. BJOG 2000;107:335-339.
36. French RS, Cowan FM, Mansour D, et al. Levonorgestrel-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG 2000;107:1218-1225.
37. Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception 2003;67:87-91.
38. Chiou CF, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. Contraception 2003;68:3-10.
39. Xiao B, Wu SC, Chong J, et al. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia. Fertil Steril 2003;79:963-969.
40. McGavigan CJ, Dockery P, Metaxa-Mariatou V, et al. Hormonally mediated disturbance of angiogenesis in the human endometrium after exposure to intrauterine levonorgestrel. Hum Reprod 2003;18:77-84.
41. Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996;54:201-208.
42. Roopa BA, Loganath A, Singh K. The effect of a levonorgestrel-releasing intrauterine system on angiogenic growth factors in the endometrium. Hum Reprod 2003;18:1809-1819.
43. Nilsson CG. Comparative quantitation of menstrual blood loss with a d-norgestrel-releasing IUD and a Nova-T-copper device. Contraception 1977;15:379-387.
44. Scholten PC, Christaens GC, Haspels AA. Intrauterine steroid contraceptives. Wien Med Wochenschr 1987;137:479-483.
45. Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65:129-132.
46. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61: 70-77.
47. Nilsson CG. Fertility after discontinuation of levonorgestrel-releasing intrauterine devices. Contraception 1982;25:273-278.
48. Belhadj H, Sivin I, Diaz S, et al. Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device. Contraception 1986;34:261-267.
49. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992;46:575-584.
50. Burkman RT. Association between intrauterine device and pelvic inflammatory disease. Obstet Gynecol 1981;57:269-276.
51. NDA 21-225: Integrated Summary of Benefits and Risks: LNG-Releasing Intrauterine System. Montville, NJ: Berlex Laboratories, Inc.
52. Kani J, Adler MW. Epidemiology of pelvic inflammatory disease. In: Berger GS, Westrom LV, eds. Pelvic Inflammatory Disease. New York: Raven Press Ltd; 1992:8-21.
53. Hubacher D, Grimes DA. Noncontraceptive health benefits of intrauterine devices: a systematic review. Obstet Gynecol Surv 2002;57:120-128.
54. Mirena [package insert]. Montville, NJ: Berlex Laboratories, Inc; 2000.
55. Backman T, Rauramo I, Huhtala S, et al. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50-54.
56. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-298.
57. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001;357:273-277.
58. Barrington JW, Arunkalaivanan AS, Abdel-Fattah M. Comparison between the levonorgestrel intrauterine system (LNG-IUS) and thermal balloon ablation in the treatment of menorrhagia. Eur J Obstet Gynecol Reprod Biol 2003;108: 72-74.
59. Nagrani R, Bowen-Simpkins P, Barrington JW. Can the levonorgestrel intrauterine system replace surgical treatment for the management of menorrhagia? BJOG 2002;109:345-347.
60. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991;164: 879-883.
61. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998;105:592-598.
62. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456-1463.
63. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995;52:269-276.
64. Scottish Hysteroscopy Audit Group. A Scottish audit of hysteroscopic surgery for menorrhagia: complications and follow up. Br J Obstet Gynaecol 1995;102:249-254.
65. Faundes A, Alvarez F, Brache V, et al. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynaecol Obstet 1988;26:429-433.
66. Robboy SJ, Bradley R. Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 1979;54:269-277.
67. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-313.
68. Andersson K, Mattsson LA, Rybo G, et al. Intrauterine release of levonorgestrel-a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963-967.
69. Suhonen SP, Allonen HO, Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995;172:562-567.
70. Suhonen S, Holmstrom T, Lahteenmaki P. Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstet Gynecol Scand 1997;76:145-150.
71. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001;76: 969-973.
72. Mercorio F, De Simone R, Di Spiezio SA, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menormagia. Contraception 2003;67:277-280.
73. Grigorieva V, Chen-Mok M, Tarasova M, et al. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003;79:1194-1198.
74. Frontino G, Vercellini P, De Giorgi O, et al. Levonorgestrel-releasing intrauterine device (LNG-IUD) versus expectant management after conservative surgery for symptomatic endometriosis. A pilot study. Fertil Steril 2002;77(suppl 1): S25-S26.
75. Lockhat FB, Emembolu J, Konju JC. The effect of a levonorgestrel intrauterine system (LNG-IUS) on symptomatic endometriosis. Fertil Steril 2002;77(suppl 1):S24.
76. Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril 2003;80: 305-309.
77. Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel- releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001;75:485-488.
78. Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999;60:173-175.
79. Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997;68:426-429.